ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

DDDD 4d Pharma Plc

16.36
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 16.36 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

4d Pharma PLC Presentation of Blautix IBS Phase II at DDW 2021

17/05/2021 7:00am

RNS Non-Regulatory


TIDMDDDD

4d Pharma PLC

17 May 2021

4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021

Company will host conference call on Tuesday, May 25, 2021 at 12:00 p.m. EDT

Leeds, UK, May 17, 2021 , - 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that it will present data from its Phase II study of single strain LBP Blautix(R) in patients with irritable bowel syndrome (IBS) subtypes IBS-C and IBS-D in a poster session at Digestive Disease Week (DDW) 2021, taking place virtually May 21-23, 2021.

Details of the poster presentation are as follows:

Presentation Title : A Phase II Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with Subtypes IBS-C and IBS-D.

Session Date & Time : Saturday, May 22, 2021 from 12:15pm to 1:00pm EDT (5:15pm to 6:00pm BST)

Session Title : Microbial-Based Therapy

Presenter : Eamonn Quigley, M.D. Chief, Division of Gastroenterology and Hepatology at Houston Methodist

Abstract Number : 3525656

4D pharma will host a virtual event to review the additional data presented at DDW 2021 and how this relates to the current IBS treatment landscape. The event will take place on Tuesday, May 25, 2021 at 5:00pm BST (12:00pm EDT). The event will feature a presentation from 4D pharma management followed by an analyst Q&A session.

A live webcast of the event will be available via the Events section of the 4D pharma website at www.4dpharmaplc.com. To access the call, please dial +1-760-294-1674 (United States) or +44-203-059-58-69 (United Kingdom) and reference Conference ID 20210360. A replay of the webcast will be available following the event.

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx(R), that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19, and Blautix(R) in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com

Contact Information:

4D pharma

Investor Relations: ir@4dpharmaplc.com

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Philip Davies / Iqra Amin / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

Stern Investor Relations, Inc. +1-212-362-1200

Julie Seidel Julie.seidel@sternir.com

Image Box Communications +44 (0)20 8943 4685

Neil Hunter / Michelle Boxall

neil@ibcomms.agency / michelle@ibcomms.agency

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRADKABNOBKDCPD

(END) Dow Jones Newswires

May 17, 2021 02:00 ET (06:00 GMT)

1 Year 4d Pharma Chart

1 Year 4d Pharma Chart

1 Month 4d Pharma Chart

1 Month 4d Pharma Chart

Your Recent History

Delayed Upgrade Clock